The Sun is Out: Will Avandia Stay in the Shadow?

Jessica Cherian, PharmD, RPh

Will the FDA go back on a decision it made years ago? I am referring to a story that has a lot of buzz: whether or not the FDA will take recommendations from its advisory committee and change the restrictions on Avandia (rosiglitazone). Avandia was approved in 1999 and shortly became the top-selling type 2 diabetes medication in the world. In 2010, data from a number of trials convinced the FDA to severely restrict the medication through implementation of a Risk Evaluation and Mitigation Strategy (REMS), while Europe banned it entirely. Following this decision, the FDA required that GSK appoint an independent organization to conduct a re-evaluation, also known as re-adjudication, of the Rosiglitazone for Cardiac Outcomes and Regulations of Glycemia in Diabetes (RECORD) trial.

An advisory committee gathered last month to review the results of the readjudication, which was conducted by the Duke Clinical Research Institute. The result was a majority of panel members favoring the modification or removal of the REMS. At the time of the RECORD trial, there had been a lack of uniform definitions for cardiovascular endpoints. Since then, the FDA has made efforts to create standard definitions for cardiovascular endpoints and methods to collect cardiovascular event data in clinical trials.

The FDA briefing document on the re-adjudication of the trial still points out other limitations of the study such as its open-label, non-inferiority design. In addition, critics have implied that the re-adjudication was also flawed, considering GSK provided Duke with the files that were needed. I am certain pharma is taking notes on many aspects of this controversial case. We are likely to see diabetes on the rise as, well as novel therapies. Companies can determine from situations like this how to effectively assess and present safety data, particularly cardiovascular outcomes in this patient population. The suggestions of the panel are not binding, and time will tell what what role the votes play in the FDA’s decision. It is a shame, though, because regardless of whether Avandia can emerge from its dark shadow, there is no amount of SPF that can protect GSK from the burns it has already endured.

Jessica Cherian, PharmD, RPh, is a clinical adjunct faculty member at Temple University in Philadelphia and is a community pharmacist.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.